// App-Quantinova.ai

e16533 : Association of FGFR alterations with FGFR 1-4 gene expression in TUR biopsies and matched NMP22 urine levels in early bladder cancer of the prospective real world clinico-pathological register trial: BRIDGister.

Researchers

Presenter

  • Ralph M. Wirtz

Principal Investigators

  • Frank Friedersdorff

  • Elke Veltrup

  • Ergin Kilic

  • Richard Watts

  • Ronny Kellner

  • Roland Hake

  • Sebastian Eidt

  • Jenny Roggisch

  • Stefan Koch

  • Thorsten Ecke

Medical Centers

  • STRATIFYER Molecular Pathology GmbH, Cologne, Germany

  • Department of Neurosurgery, Charite Universitatsmedizin Berlin, Berlin, Germany

  • Institut für Pathologie am Klinikum Leverkusen, Leverkusen, Germany

  • Qiagen Inc, Crawley, United Kingdom

  • QiagenGmbH, Hilden, Germany.

  • Department of Pathology, St. Elisabeth Hospital Koln-Hohenlind, Cologne, Germany

  • Helios Hospital, Bad Saarow, Germany

  • HELIOS Hospital, Bad Saarow, Germany

Locations

  • Germany

  • United Kingdom

Companies

  • STRATIFYER Molecular

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bladder Cancer

Biomarkers

  • Nuclear mitotic apparatus protein 1

  • Proteasome Subunit Beta 8

  • Cytokeratin 5

  • erb-b2 receptor tyrosine kinase 2

  • Fibroblast growth factor receptor

  • Fibroblast growth factor receptor 1

  • Fibroblast Growth Factor Receptor 2

  • Fibroblast growth factor receptor 3

  • Fibroblast growth factor receptor 4

  • Ribosomal Protein S27a

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Prospective

Phase

  • N/A

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved